Aligo Venture Capital’s portfolio company, Prosoma, has raised €4.4 million in a pre-Series A funding round to further develop its digital solutions supporting oncology care. The round was led by Impact Ventures and Verge HealthTech Fund, with participation from Convergence Partners, Smartlink Partners, and Simpact Ventures.

The funds will be used to scale operations in the DACH region and expand the company’s presence in the U.S. market. Prosoma develops the certified medical application Living Well Plus, which offers personalized psycho-oncological support for cancer patients. Clinically validated, the solution reduces anxiety, stress, and depression symptoms by 25–50%, while also lowering the need for traditional in-person medical consultations.

The company is experiencing dynamic growth – in 2024, it supported nearly 3,000 patients, generated €1 million in revenue, and expanded partnerships with over 30 organizations in the DACH region as well as leading U.S. institutions, including Cedars-Sinai.

This funding round confirms the growing importance of digital solutions in oncology and strengthens Prosoma’s position in psycho-oncological support and improving patients’ quality of life.